Global Generic Leader 'Teva' Sells $5 Million in Company Shares

On May 1, 2026, Mark Sabag, Vice President and Head of International Commercial Markets at Teva Pharmaceutical Industries Ltd. (TEVA), sold approximately 140,000 shares of the company’s common stock at about $34.99 per share, generating roughly $5 million in proceeds (approximately KRW 70 billion).

As a result, Sabag’s direct holdings declined to around 80,000 shares, valued at approximately $2.8 million (KRW 40 billion) based on the reported transaction price.

On April 29, Teva reported first-quarter 2026 results, posting revenues of about $4 billion (KRW 5 trillion) and improved profitability, with sales of its core innovative medicines—AUSTEDO, AJOVY and UZEDY—achieving double-digit growth.

That same day, Teva announced an agreement to acquire Emalex Biosciences, owner of Ecopipam, a pediatric Tourette syndrome treatment candidate, for up to $900 million (KRW 1.2 trillion), expanding its neuroscience pipeline.

Founded in 1935 and headquartered in Tel Aviv, Israel, Teva is the world’s largest generic pharmaceutical manufacturer, dual-listed on the New York Stock Exchange and the Tel Aviv Stock Exchange.

Building on its extensive generics business, Teva is pursuing a “Pivot to Growth” strategy centered on CNS innovative therapies such as AUSTEDO for Huntington’s chorea and movement disorders and AJOVY for migraine prevention.